Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug
Novo’s ongoing efforts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
James Waldron
Sep 29, 2026 3:50am
Fierce Pharma
Novo struggles to appease restless investors with new strategy
Sep 21, 2026 10:50am
Novo corrals 3 new early-stage obesity drugs from Kallyope
Sep 18, 2026 11:23am
Fierce Pharma
Novo CEO talks embracing change and staying bullish amid rebrand
Sep 17, 2026 8:45am
Novo explores macrocycle potential in $1.4B Danish biotech pact
Sep 17, 2026 7:00am
Novo scraps $285M pact with Ascendis to develop monthly GLP-1
Sep 15, 2026 5:19am
